Loretta Fala, Medical Writer

Authored Items
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, News & Updates, Leukemia
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, News & Updates, Breast Cancer
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals in FDA Approvals, News & Updates, Lymphoma
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala, Medical Writer
2017 Oncology Pharmacy Guide to New FDA Approvals in Drug Profiles
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala, Medical Writer
2016 Oncology Pharmacy Guide to New FDA Approvals in Drug Profiles
Last modified: May 12, 2016